Peer Exchange

Panelists discuss modern multidisciplinary strategies in neuroendocrine tumors, with a focus on evolving guidelines, immunotherapy, and patient-centered care.

• Explore the current treatment landscape of muscle-invasive bladder cancer
• Examine the emerging role of ctDNA and MRD testing in bladder cancer disease monitoring and treatment selection
• Discuss strategies for implementing novel testing approaches into clinical practice

Panelists discuss the evolving multidisciplinary management of cutaneous squamous cell carcinoma, emphasizing diagnostic precision, timely referral, and the expanding role of immunotherapy and coordinated care in improving outcomes for high-risk and advanced disease.

Panelists discuss the evolving management of advanced and metastatic non–small cell lung cancer driven by key oncogenic alterations, emphasizing advancements in molecular diagnostics, targeted treatment development, resistance mechanisms, and personalized sequencing strategies that continue to redefine the modern standard of care.

Panelists are going to discuss recent updates in the treatment of breast cancer, focusing on the key updates for HER2-targeting therapies. We will discuss the data in the context of the evolving landscape and its impact on clinical practice.

Panelists discuss how comprehensive biomarker testing is essential for all patients with early-stage non–small cell lung cancer, with thoracic specialists emphasizing the importance of testing primary tumor samples and lymph nodes to identify actionable mutations that guide treatment decisions and inform patients about their therapeutic journey, particularly as targeted therapies and immunotherapies continue to advance in early-stage and locally advanced disease settings.

Panelists discuss how durvalumab consolidation has become standard of care for limited-stage small cell lung cancer following the ADRIATIC trial while emphasizing the importance of ensuring all eligible patients receive first-line immunotherapy in extensive-stage disease, managing emerging toxicities like pneumonitis through multidisciplinary collaboration, implementing novel therapies such as tarlatamab with appropriate infrastructure and patient selection, and optimizing sequencing strategies for the expanding arsenal of treatments including antibody-drug conjugates, T-cell engagers, and investigational agents that are transforming the previously limited therapeutic landscape of this aggressive malignancy.

Experts explore the current frontline treatment options for EGFR-targeted therapy, examine when combination therapy may be preferred, and discuss the importance of appropriately sequencing therapies for our patients.

Panelists discuss the limitations of conventional IHC in assessing TROP2 expression, the advantages of Quantitative Continuous Scoring (QCS) in improving detection accuracy, emerging clinical data supporting TROP2 NMR as a predictive biomarker for Dato-DXd, and future considerations for integrating these tools into patient selection and treatment strategies.

Callie Coombs, MD; Nicole Lamanna, MD; Sameer A. Parikh, MBBS; Joanna M. Rhodes, MD, MSCE; and Mazyar Shadman, MD, MPH, discuss how to optimize chronic lymphocytic leukemia (CLL) treatment by incorporating prognostic biomarkers like TP53 status and IGHV mutation testing into therapy selection, weighing the benefits of continuous Bruton tyrosine kinase inhibitor therapy vs fixed-duration oral doublet regimens, managing treatment toxicities and resistance patterns, and sequencing therapies in the relapsed/refractory setting based on emerging clinical trial data presented at the European Hematology Association 2025 Congress (EHA 2025).

Sagar Lonial, MD, FACP, FASCO; Adrianna Rossi, MD; Ajay K. Nooka, MD, MPH, FACP; and Cesar Rodriguez, MD, discuss how evolving treatment strategies in multiple myeloma are shifting toward quadruplet therapy regimens for newly diagnosed patients, with CAR T-cell therapy being used increasingly in earlier lines of treatment for high-risk disease. They emphasize the importance of achieving MRD negativity and personalizing treatment approaches based on patient fitness rather than strict transplant eligibility criteria.

Petros Grivas, MD, PhD; Rana R. McKay, MD; Alicia Morgans, MD, MPH, and Neal Shore, MD, FACS discuss how to personalize treatment intensification in metastatic castration-sensitive prostate cancer by considering clinical factors like disease volume, patient fitness, genomic biomarkers, and emerging trial data to guide decisions between doublet versus triplet therapy regimens.

Tina Cascone, MD, PhD; Josh Reuss, MD; Wade Iams, MD, MSCI; Aditya Juloori, Tina Cascone, MD, PhD; Josh Reuss, MD; Wade Iams, MD, MSCI; Aditya Juloori, MD; Brendon Stiles, MD; and Mara Antonoff, MD, FACS, discuss how the evolving landscape of early-stage non–small cell lung cancer (NSCLC) treatment has been transformed by neoadjuvant and perioperative chemoimmunotherapy approaches, with recent data presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting from CheckMate 816 and CheckMate 77T demonstrating significant overall survival benefits while highlighting the critical importance of multidisciplinary collaboration, biomarker-guided personalization, and managing surgical attrition rates to optimize patient outcomes.

Panelists discuss the significant advancements in metastatic melanoma treatment over the past decade, including targeted therapies and immunotherapy, to help clinicians navigate the evolving therapeutic landscape and improve patient outcomes.

Sam Klempner, MD; Michael K. Gibson, MD, PhD; Kaitlyn Kelly, MD, MAS; and Nataliya Uboha, MD, PhD, discuss how the positive results from the phase 3 MATTERHORN trial, which demonstrated that adding durvalumab to perioperative FLOT chemotherapy significantly improved event-free survival in patients with resectable gastric and gastroesophageal junction cancers, establishes a new standard of care that they plan to implement in clinical practice while addressing practical considerations around patient selection, multidisciplinary coordination, and managing the toxicity profile of this combination regimen.

Panelists discuss the evolving landscape of breast cancer surveillance, focusing on circulating tumor DNA testing for molecular residual disease detection, recent clinical data supporting its use, and practical strategies for integrating this technology into posttreatment monitoring.

Panelists discussed evolving strategies in limited-stage and extensive-stage small cell lung cancer (LS-SCLC and ES-SCLC), including the integration of consolidation durvalumab in LS-SCLC, emerging first-line chemoimmunotherapy regimens in ES-SCLC, maintenance strategies such as atezolizumab plus lurbinectedin and durvalumab plus tarlatamab (DeLLphi-305), and the promising future role of novel agents like T-cell engagers, antibody-drug conjugates, and B7-H3–targeted therapies (including DeLLphi-304) in reshaping the treatment landscape.

Shreyaskumar R. Patel, MD; Priscilla Merriam, MD; Richard F. Riedel, MD; and Gina Z. D'Amato, MD, discuss how gastrointestinal stromal tumors require comprehensive mutational analysis to guide targeted kinase inhibitor therapy, emphasizing the importance of patient adherence, proactive adverse effect management, and maintaining some form of kinase inhibition even after progression to maximize disease control and quality of life.